COVID-19: Pakistanis line up for final trials of Chinese vaccine
- Pakistanis are rushing to test centers for third phase trials for China-made vaccine
- Ad5-nCoV is a vaccine being developed by China's CanSinoBio
- The vaccine was announced safe during mid-stage trial n July
Thousands of Pakistanis are lining up at health facilities for the Chinese coronavirus vaccine trials, which has entered its final phase, reported AFP.
The vaccine development for coronavirus has taken a fresh turn in last two weeks, during which at least three makers announced obtaining successful results—allowing the humanity a collective sigh of relief.
The vaccines that made the claim included the ones built by Moderna, Pfizer/BioNTech, and Oxford University/AstraZeneca.
The Chinese vaccine under trial in Pakistan is being developed by CanSinoBio and the Beijing Institute of Biotechnology China.
China has chosen Pakistan as one of the locations for their vaccine trial, even as the country’s previous stints with vaccine development cast a doubt somewhat on their effective handling of the trials.
"I have volunteered myself for a noble cause that will help humanity," AFP quoted a volunteer at Islamabad's Shifa hospital, where hundreds of participants are being paid about $50 for their trouble.
Others should "step forward and take part in this noble cause which will save lives," he added, according to the agency.
China has treated Pakistan as its strategic partner for long and has initiated development projects within it and along its border with construction of roads etc.
"We hope to have some findings ready about the accuracy and efficacy of the vaccine in two to three months," Ejaz Ahmad Khan, the principal researcher overseeing the trial in Pakistan, told AFP.
The agency said Pakistan has already inoculated about 7,000 of the 10,000 participants registered to take the jab.
Pakistan has so far confirmed more than 382,000 cases and 7,800 deaths since the virus began to spread across the globe in February.